Lymphovascular space invasion and Estrogen Receptor status in high-grade serous ovarian cancer-a multicenter study by the FRANCOGYN group - 26/10/21

Doi : 10.1016/j.jogoh.2021.102242

Jerome Lorenzini ¹, Marion Deberti ¹, Gilles Body ^1,², Xavier Carcopino ³, Cyril Touboul ⁴, Yohann Dabi ⁴, Pierre Collinet ⁵, Charles Coutant ⁶, Cherif Akladios ⁷, Vincent Lavoué ⁸, Pierre-Adrien Bolze ⁹, Cyrille Huchon ¹⁰, Alexandre Bricou ¹¹, Geoffroy Canlorbe ¹², Camille Mimoun ¹³, Sofiane Bendifallah ¹⁴, Lobna Ouldamer ^1,^2,^⁎
FRANCOGYN Research Group
¹ Department of Gynecology, Tours University Hospital, Tours, France
² INSERM U1069 Université François-Rabelais, Tours, France
³ Department of Obstetrics and Gynecology, Hôpital Nord, APHM, Aix-Marseille University (AMU), Univ Avignon, CNRS, IRD, IMBE UMR 7263, 13397, Marseille, France
⁴ Department of Obstetrics and Gynecology, Centre Hospitalier Intercommunal, Creteil, France
⁵ Department of Gynecologic surgery, Jeanne de Flandre Hospital, CHRU LILLE, Rue Eugene Avinée 59037 Lille Cedex, France
⁶ Department of Surgical Oncology, Georges-Francois Leclerc Cancer Centre, Dijon, France
⁷ Department of Surgical Gynecology, Strasbourg University Hospital, Strasbourg, France
⁸ Department of Gynecology, Rennes University Hospital, France. INSERM 1242, COSS, Rennes. Université de Rennes 1. France
⁹ Department of Gynecologic and Oncologic Surgery and Obstetrics, Lyon Sud University Hospital, Hospices Civils de Lyon, Université Lyon 1, France
¹⁰ Department of gynecology, CHI Poissy-St-Germain, Université Versailles-Saint-Quentin en Yvelines, EA 7285 Risques cliniques et sécurité en santé des femmes, Université Versailles-Saint-Quentin en Yvelines, Versailles, France
¹¹ Department of Gynecology, Bobigny University, AP-HP, Jean-Verdier Hospital, Bondy, France
¹² Department of Gynecologic and Breast Surgery and Oncology, AP-HP, Pitié-Salpêtrière, University Hospital, Paris, France
¹³ Department of Gynecology and Obstetrics, Lariboisiere Hospital, 750019 Paris, France
¹⁴ Department of Gynecology and Obstetrics, Tenon University Hospital, Assistance Publique des Hôpitaux de Paris (AP-HP), Paris, France

^⁎Corresponding author: Lobna Ouldamer, Service de Gynécologie, 2 Boulevard Tonnellé, 37044 Tours (France), Phone: +33 2 47 47 47 41, Fax: +33 2 47 47 92 73Service de Gynécologie2 Boulevard TonnelléTours37044France

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Tuesday 26 October 2021
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

ABSTRACT

Background

The aim of this study was to evaluate the impact of Lymphovascular Space Invasion (LVSI) on Overall Survival (OS) and Recurrence-Free Survival (RFS) in patients managed for high-grade serous epithelial ovarian cancer (HGSOC).

Materials and methods

Retrospective multicenter study by the FRANCOGYN research group between January 2001 and December 2018. All patients managed for HGSOC and for whom histological slides for the review of LVSI were available, were included. The characteristics of patients with LVSI (LVSI group) were compared to those without LVSI (No LVSI group). A Cox analysis for OS and RFS analysis was performed in all populations.

Results

Over the study period, 410 patients were included in the thirteen institutions. Among them, 289 patients had LVSI (33.9%). LVSI was an independent predictive factor for poorer Overall and Recurrence-Free Survival. LVSI affected OS (p<0.001) and RFS (p<0.001), Association of LVSI status and estrogen receptor status (ER) also affected OS and RFS (p=0.04; p=0.04 respectively).